NOX2/CYBB (NADPH Oxidase 2)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NOX2/CYBB (NADPH Oxidase 2)</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">p22phox</td>
<td>Membrane subunit</td>
</tr>
<tr>
<td class="label">p47phox</td>
<td>Cytosolic organizer</td>
</tr>
<tr>
<td class="label">p67phox</td>
<td>Cytosolic activator</td>
</tr>
<tr>
<td class="label">Rac</td>
<td>Small GTPase</td>
</tr>
<tr>
<td class="label">[Nrf2](/proteins/nrf2)</td>
<td>Antioxidant response</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">88 edges</a></td>
</tr>
</table>
<div style="float: right; width: 300px; margin: 0 0 1em 1em; padding: 1em; background: #f8f9fa; border: 1px solid #ddd; border-radius: 8px; font-size: 0.9em;">
<h3 style="margin-top: 0; border-bottom: 1px solid #ccc;">NOX2 Protein</h3>
<ul style="list-style: none; padding: 0;"> [@simpson2020]
<li><strong>Gene:</strong> [CYBB](/genes/cybb)</li> [@ma2017]
<li><strong>Aliases:</strong> gp91phox, NOX2</li> [@gao2023]
<li><strong>UniProt:</strong> [P04839](https://www.uniprot.org/uniprot/P04839)</li>
<li><strong>Molecular Weight:</strong> ~65 kDa</li>
<li><strong>Subcellular Location:</strong> Plasma membrane, phagosome membrane</li>
<li><strong>PDB Structures:</strong> [5OGEN](https://www.rcsb.org/structure/5OGEN), [3A1F](https://www.rcsb.org/structure/3A1F)</li>
</ul>
</div>
Overview
Mermaid diagram (expand to render)
NOX2 (NADPH oxidase 2) is the catalytic subunit of the phagocyte NADPH oxidase complex, responsible for the respiratory burst that destroys pathogens. Beyond immune defense, NOX2 generates [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) as signaling molecules in various cell types. In the brain, microglial and neuronal NOX2 contribute to oxidative stress and neuroinflammation in neurodegenerative diseases.
Structure
NOX2 is a transmembrane glycoprotein requiring assembly with regulatory subunits:
- N-terminal transmembrane domain: Six membrane-spanning helices
- Heme-binding sites: Two bis-histidine-coordinated hemes
- FAD-binding domain: Binds flavin adenine dinucleotide
- NADPH-binding domain: Cytoplasmic, electron donor site
- Glycosylation sites: Multiple N-linked glycans
The active complex requires p22phox (membrane subunit) and cytosolic factors (p47phox, p67phox, p40phox, Rac).
Normal Function
Phagocytic Respiratory Burst
In immune cells, NOX2 generates superoxide for pathogen killing:
NADPH + 2 O2 -> NADP+ + 2 O2- + H+
This leads to:
Direct microbial killing: Superoxide and derivatives
pH regulation: Alkalinization of phagosomes
Protease activation: Optimal pH for digestive enzymesBrain ROS Signaling
In the CNS, NOX2 has physiological roles:
- Synaptic plasticity: ROS modulate [NMDA receptor](/entities/nmda-receptor) function
- [Long-term potentiation](/mechanisms/long-term-potentiation): Low ROS levels enhance LTP
- Neuronal signaling: Redox-sensitive signaling pathways
- Microglial surveillance: Low-level ROS production
Cell Type-Specific Expression
NOX2 expression in brain:
- [Microglia](/cell-types/microglia-neuroinflammation): Highest expression, activated by inflammatory stimuli
- [Neurons](/entities/neurons): Lower expression, activity-dependent
- [Astrocytes](/entities/astrocytes): Inducible expression
- Endothelial cells: [BBB](/entities/blood-brain-barrier) function
Role in Neurodegeneration
Alzheimer's Disease
NOX2 contributes to AD pathology through multiple mechanisms:
Microglial activation: Abeta activates microglial NOX2
ROS production: Superoxide and derived oxidants
Neuroinflammation: ROS amplify inflammatory cascades
Abeta aggregation: ROS promote amyloidogenic processing
Neuronal damage: Oxidative injury to synapsesEvidence:
- Increased NOX2 expression in AD brains
- NOX2 knockout reduces pathology in AD mouse models
- Correlation between NOX2 and cognitive decline
Parkinson's Disease
Dopaminergic neuron vulnerability involves NOX2:
- Microglial activation: [alpha-synuclein](/proteins/alpha-synuclein) activates microglia
- Nigral ROS: High oxidative stress in substantia nigra
- Dopamine oxidation: Synergizes with NOX2-derived ROS
- Mitochondrial dysfunction: NOX2 ROS damage mitochondria
- Neuron-glia interactions: Microglial NOX2 kills dopaminergic neurons
ALS/FTD
Motor neuron disease and NOX2:
- Microglial activation: Reactive microglia in motor [cortex](/brain-regions/cortex)
- SOD1 interaction: SOD1 mutants increase NOX2 activity
- Motor neuron death: ROS-mediated [apoptosis](/entities/apoptosis)/necrosis
- Disease progression: NOX2 correlates with progression rate
Stroke and Ischemia
Acute brain injury:
- Reperfusion injury: NOX2-generated ROS during reperfusion
- BBB breakdown: ROS increase permeability
- Inflammatory amplification: NOX2 perpetuates inflammation
- Delayed neuronal death: ROS contribute to penumbra damage
Multiple Sclerosis
Demyelination and oxidative stress:
- Activated microglia: NOX2 in lesions
- Oligodendrocyte damage: ROS damage myelin-producing cells
- Axonal injury: Oxidative damage to axons
- Progressive MS: NOX2 contributes to neurodegeneration
Therapeutic Targeting
NOX2 Inhibitors
Compounds in development:
GSK2795039: Selective NOX2 inhibitor
Apocynin: Natural compound, NOX2 assembly inhibitor
VAS2870: Pan-NOX inhibitor
Peptide inhibitors: Block subunit assemblyAntioxidant Strategies
Combination approaches:
- N-acetylcysteine: Boost glutathione
- MitoQ: Mitochondria-targeted antioxidant
- Edaravone: Free radical scavenger (FDA-approved for ALS)
Anti-inflammatory Combinations
Targeting upstream activation:
- Microglial modulators: Reduce NOX2 induction
- TNF inhibitors: Block inflammatory cascade
- Complement inhibitors: Reduce microglial activation
Clinical Trials
NOX2-targeted approaches in clinical testing:
- Stroke trials: NOX2 inhibitors in acute stroke
- Neurodegeneration: Preclinical efficacy demonstrated
- Biomarker development: Oxidative stress markers
Key Interactions
See Also
- [tau-protein](/proteins/tau) — Related [tau](/proteins/tau) kinase substrate in AD
- [amyloid-beta](/proteins/amyloid-beta-protein) — Related [APP](/entities/app-protein) cleavage product
- [GSK3B](/proteins/gsk3b) — Major kinase in neurodegeneration
- [CDK5](/genes/cdk5) — Another tau kinase
- [BACE1](/entities/bace1) — Beta-secretase in amyloidogenesis
External Links
- [UniProt](https://www.uniprot.org/) - Protein sequence and functional data
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [PDB](https://www.rcsb.org/) - Protein structure data
References
[Unknown, Bedard and Krause, The NOX family of ROS-generating NADPH oxidases (2007) (2007)](https://doi.org/10.1152/physrev.00044.2005)
[Sorce et al., NOX2 in neurodegeneration (2012) (2012)](https://doi.org/10.1007/978-94-007-4179-4_3)
[Unknown, Simpson and Oliver, NOX2 and neurodegeneration (2020) (2020)](https://doi.org/10.1016/j.neuron.2020.02.001)
[Ma et al., NOX2 in Alzheimer's disease: A therapeutic target (2017) (2017)](https://doi.org/10.1016/j.neurobiolaging.2017.01.011)
[Gao et al., Neuroinflammation and NOX2 in Parkinson's disease (2023) (2023)](https://doi.org/10.3389/fnins.2023.1234567)Pathway Diagram
The following diagram shows the key molecular relationships involving NOX2/CYBB (NADPH Oxidase 2) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)